unchanged from baseline after vaccination. Mean local reaction at initial inoculation was 28 ± 10 mm, increasing to 68 ± 8 mm at the final inoculation (p \ 0.01). Mean ELISPOT response to GP2 increased from 47 ± 19 at baseline to 144 ± 60 (p = 0.13) after vaccination. Based on safety and immunologic data, the appropriate dose was determined to be 1000 lg of GP2 ? 250 lg of GM-CSF. Conclusion. The GP2 ? GM-CSF vaccine is safe and stimulates an immunologic response when administered concurrently with trastuzumab. An ongoing phase II trial is evaluating the efficacy of combining a CD8 T-cell-eliciting vaccine with trastuzumab in HER2-positive breast cancer patients.
Trastuzumab, a human immunoglobulin (Ig) G1 monoclonal antibody that targets the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein, is routinely administered to HER2-positive breast cancer patients. Trastuzumab functions via multiple mechanisms, including decreasing signaling by preventing HER2 dimerization, increasing endocytic destruction of the HER2 receptor, and inhibiting extracellular domain shedding. 1, 2 Immune-mediated mechanisms of action have also been described, including antibody-dependent cellular cytotoxicity (ADCC). 3, 4 ADCC leads to antigen release, triggering uptake and cross-presentation by dendritic cells, stimulating an anti-HER2 CD8? T-cell response. 5, 6 Trastuzumab also stimulates endogenous anti-HER2 antibody and anti-HER2 CD4? T-cell responses. 7, 8 The GP2 (HER2: 654-662) peptide vaccine is comprised of the human leukocyte antigen (HLA)-A2-and A3-restricted, HER2-derived peptide GP2 combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF). Early-phase trials demonstrated the vaccine to be both safe and capable of generating a HER2-specific CD8? T-cell response. 9, 10 The phase II trial randomized HLA-A2/A3? breast cancer patients with any level of HER2 expression (immunohistochemistry [IHC] 1-3?) in their tumor to receive 6-monthly inoculations of GP2 ? GM-CSF or GM-CSF alone, with booster inoculations every 6 months thereafter. An intention-totreat analysis performed at a median follow-up of 34 months showed an 88% estimated 5-year disease-free survival (DFS) rate in vaccinated patients versus 81% in GM-CSF-only patients (p = 0.43). 10 In HER2-positive patients (all received trastuzumab) DFS was 94% in the vaccinated patients compared with 89% in the GM-CSFonly patients (p = 0.86). Per-treatment analysis, which excluded recurrences during the primary vaccination series and secondary malignancies, showed 100% DFS in vaccinated HER2-positive patients compared with 89% in GM-CSF-only patients (p = 0.08). Breast cancer recurrences only occurred during the primary vaccination series, which was administered after completing standard therapy to include trastuzumab. Given this, we hypothesized that by administering the vaccine earlier, concurrently with trastuzumab, the stimulated immune response may prevent early recurrences.
In this study, we describe a phase I trial (NCT03014076) designed to evaluate the combination of GP2 ? GM-CSF administered concurrently with trastuzumab. The primary objective was to determine the safety of the combination, while secondary objectives were to determine dosing and immunologic response.
PATIENTS AND METHODS

Patient Characteristics and Clinical Protocol
This single-center, phase Ib, dose-escalation trial was conducted under an investigational new drug application (BB-IND #11730). Eligible patients had to have histologically confirmed, stage I-III HER2-positive breast cancer and be receiving trastuzumab as part of their therapy. HER2-positive was defined as IHC 3? or a fluorescence in situ hybridization ratio [2.0 (study enrolled prior to guideline changes). Enrollment occurred any time after diagnosis, however initiation of study treatment occurred after completion of surgery, chemotherapy, and radiation, such that the vaccination series overlapped with the trastuzumab monotherapy portion of the treatment regimen.
Because GP2 is HLA-A2 and HLA-A3 restricted, after initial consent for screening, each patient's HLA-A2 and HLA-A3 status was determined. HLA-A2? and HLA-A3? patients were eligible to sign a treatment consent and participate in the study.
The study was a 3 ? 3 phase dose escalation/optimization trial with three patients enrolled in each of four dosing cohorts, with an expansion cohort at the maximum delivered dose (MDD) ( Table 1) . Expansion was performed at the MDD because there was no dose-limiting toxicity at any of the lower doses. A higher dose could not be administered due to the volume required to solubilize the peptide for injection. The primary objective was to determine the safety of the combination therapy, while secondary objectives included determining dosing and immunologic responses. The study was approved by the MD Anderson Cancer Center Institutional Review Board.
Vaccine and Vaccination Series
Good manufacturing practices grade GP2 peptide was purified to [95%. Sterility, endotoxin, and general safety testing were carried out by the manufacturer. Lyophilized peptide was reconstituted in sterile saline and mixed with GM-CSF (Berlex, Seattle, WA, USA) to a final 1 ml volume. The primary vaccination series consisted of six inoculations administered every 21 days with trastuzumab infusion. The 1.0 ml inoculation was divided, with 0.5 ml administered intradermally at two sites, 5 cm apart in the same lymph node draining area (upper thigh).
Toxicity
Patients were monitored for 1 h after inoculation for hypersensitivity reactions. Local and systemic toxicity was assessed 48-72 h after each inoculation. Dose-limiting toxicity was considered grade 3 or higher local or systemic toxicity, as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0.
Cardiac toxicity was monitored with echocardiograms performed prior to initiation of trastuzumab and vaccination, and every 3 months while receiving treatment. A left ventricular ejection fraction (LVEF) of C50% was required for enrollment. Per protocol, patients were discontinued from study treatment if a decrease in LVEF [10%, symptomatic congestive heart failure, or grade 3 or higher cardiac toxicity was observed.
Immune Monitoring
In vivo immune monitoring involved measuring the local reactions in two dimensions at the inoculation site using the sensitive ballpoint pen test 48-72 h after each inoculation. 11 In vitro immune monitoring was performed using an enzyme-linked immunosorbent spot (ELISPOT) assay for interferon (IFN)-c secretion in response to GP2 and a second HER2-derived peptide, AE36, to determine epitope spreading. 5 9 10 5 cells/200 lL/well freshly isolated peripheral blood mononuclear cells (PBMC) in culture medium supplemented with interleukin-7 (20 ng/ mL) were added into flat-bottom wells of antihuman IFN-c ELISPOT plates (PD Pharmingen). Duplicate wells of PBMC were stimulated in the absence (culture medium only) or presence of 25 lg/mL GP2 or AE36 overnight at 37°C ? 5% CO 2 . The plate was then processed and developed per manufacturer instructions. IFN-c-secreting cells were enumerated using the ELISPOT analyzer and Immunospot Professional Software (CTL Analyzers LLC, Shaker Heights, OH, USA). GP2 peptide-specific IFN-csecreting cells were calculated by subtracting the total number of spots in the control wells from the total number of spots in the GP2-stimulated wells. Results are presented as number of spots per 10 6 PBMCs. Laboratory staff performing the biologic assays were blinded to the patient's assigned dose level, as well as inoculation number.
Statistical Analysis
Median values were compared using the Wilcoxon rank sum test for matched samples, and means were compared with paired or unpaired t test, as appropriate.
RESULTS
Patients
Seventeen HER2-positive patients with a median age of 47 years (range 30-56) were enrolled and vaccinated. Thirteen patients (76%) had tumors larger than 2 cm, 13 (76%) were node positive, 11 (65%) were grade 3, and 10 were either estrogen or progesterone receptor positive. Eleven (65%) were HLA-A2 positive and 6 (35%) were HLA-A3 positive.
Safety
The vaccine was well tolerated, with only grade 1 and 2 local and systemic toxicity observed. As shown in Fig. 1a , for 82% of patients the maximum local toxicity was grade 1, with the remaining patients (18%) experiencing grade 2 local toxicity. The most common local toxicities included induration (100%) and pruritis (76%) at the injection site. The maximum systemic toxicity was grade 1 for 35% of patients and grade 2 for 18% of patients. The most common symptoms included headache (29%) and fatigue (29%), and 47% of patients did not experience systemic toxicity. No dose-limiting toxicities were found.
Baseline echocardiograms were obtained a median of 68 days prior to the first inoculation. The median LVEF was 60% (range 53-69%). Midway through the vaccination series (median 99 days after enrollment), the median LVEF remained at 60% (range 52-62) (Fig. 1b) . One patient experienced an asymptomatic 10% drop in LVEF (60-50% at 73 days after enrollment) that did not require holding or stopping treatment per protocol or published recommendations. Fourteen patients had echocardiograms a median of 61 days after vaccination series completion. The median LVEF was 60% (range 50-60%).
Immunologic Response
Mean local reaction after the initial inoculation was 28 ± 10 mm, which increased after each subsequent inoculation (p \ 0.02 compared with baseline). The local reaction plateaued after the fourth inoculation at a mean of 70 ± 8 mm (p = 0.001 vs. baseline), which decreased slightly to a mean of 68 ± 8 mm after the final inoculation (p \ 0.001 vs. baseline) (Fig. 2a) . Although the differences did not reach statistical significance, patients receiving the maximum dose, GP2 1000 lg ? GM-CSF 250 lg, had larger local reactions at all time points than patients in lower dose cohorts (Fig. 2b) . HLA-A2 ? patients (n = 11) had larger local reactions compared with HLA-A3 ? (n = 6) patients, with significant differences observed after the third GM-CSF granulocyte-macrophage colony-stimulating factor, MDD maximum delivered dose (71 ± 7 vs. 39 ± 13 mm, p = 0.03) and fifth inoculations (75 ± 9 vs. 36 ± 17, p = 0.04) (Fig. 2c) . Ten patients had no discernable local reaction to the initial inoculation and were considered to have no preexisting GP2 immunity. Seven patients had a measurable response to their initial inoculations, with a mean local reaction of 68 ± 14 mm. Patients without pre-existing immunity had increasingly larger local reactions over the first two inoculations. The mean local reaction plateaued at a size similar to those with pre-existing immunity after the second inoculation. For patients with pre-existing immunity, the mean local reaction size did not change significantly (Fig. 2d) . In vitro immunologic responses were assessed using the ELISPOT assay. The mean number of IFN-c secreting spots in response to GP2 increased to 144 ± 60 after completion of the vaccination series versus 46 ± 19 at baseline (p = 0.13). The spots subsequently decreased to near baseline 6-months after completion of the vaccine series, suggesting waning immunity (Fig. 3a) . No difference in ELISPOT reactions between any dosing cohorts, or based on HLA-A2 versus HLA-A3 status, was found. ELISPOT responses against the HER2-derived epitope AE37 were assessed for evidence of epitope spreading. There was an increase in the mean number of IFN-c secreting spots from pre-vaccination (25 ± 9 spots) to midvaccination (61 ± 27, p = 0.23), post-vaccination (71 ± 36, p = 0.16), and 6-months post-vaccination (67 ± 44, p = 0.30) (Fig. 3b ).
DISCUSSION
Combined with trastuzumab, the GP2 ? GM-CSF vaccine is safe, with no local or systemic toxicity greater than grade 2, and no increase in cardiotoxicity. The combination induces a dose-and HLA-type-dependent immunologic response, as well as intra-antigenic epitope spreading, suggesting a broad immune response.
The mild toxicity seen in this study parallels previous trials of GP2 ? GM-CSF alone, and is consistent with injection site reactions and systemic symptoms generated by immunologic responses to vaccinations. 9, 10 No clinically significant cardiac toxicity was observed. Transient asymptomatic declines in LVEF were seen in three patients, similar to the expected rate for trastuzumab alone.
In a trial evaluating HER2-targeted vaccination using a dendritic cell vaccine as monotherapy in patients with ductal carcinoma in situ, a transient, asymptomatic decline in cardiac function corresponding with induction of HER2-specific cellular-mediated immune responses was observed. 12 This occurred in 3 of 27 (11%) vaccinated patients. In all cases, circulating anti-HER2 antibodies were measurable before vaccination. In our trials investigating other HER2-directed vaccines, including E75 ? GM-CSF (NCT00841399, NCT00584789) and AE37 ? GM-CSF (NCT00524277), we did not observe clinically significant cardiac toxicity [13] [14] [15] [16] Additionally, HER2-directed vaccination with concurrent trastuzumab administered in the metastatic setting demonstrated a similar, low incidence of transient, asymptomatic decline in LVEF. [17] [18] [19] In this study, we show that the GP2 vaccine plus trastuzumab is capable of stimulating immunologic responses. Immunity is dose-dependent and increases rapidly in response to the initial inoculations and then plateaus later in the vaccination series, as shown in previous peptide vaccine trials. 20 Some patients experienced large local reactions to the initial inoculation, which we believe represents pre-existing immunity against GP2. In a phase II trial evaluating the GP2 peptide vaccine as monotherapy (NCT00524277), large local reactions were associated with lower recurrence rates in breast cancer patients (unpublished data). We made a similar observation in our phase II study evaluating the AE37 ? GM-CSF vaccine (NCT00524277), where a robust initial local reaction was associated with a lower recurrence rate (unpublished data). The size of the local reaction after vaccination may serve as a biomarker to predict immunologic response.
One limitation of this study is that we cannot compare the immune response generated by vaccine alone with that stimulated by vaccine plus trastuzumab, or the response generated by trastuzumab alone with that stimulated by vaccine plus trastuzumab. Our ongoing phase II trials randomizing patients to trastuzumab or trastuzumab plus vaccine will provide insight to this question. Interestingly, the local reaction to GP2 vaccine administered concurrently with trastuzumab was less robust in HLA-A3? patients than HLA-A2? patients. In a previous trial of the CD8 T-cell-eliciting E75 vaccine, HLA-A3? patients had immunological and clinical responses similar to HLA-A2? patients. 21 E75 has a higher predicted binding affinity to HLA-A2 and HLA-A3 than GP2. 22 Because GP2 is not predicted to bind as well as E75 to HLA-A2, it is considered a subdominant epitope. Despite this, in preclinical studies, our group demonstrated GP2 immunogenicity using a T2 model and by demonstrating epitope spreading to the GP2 antigen in blood samples collected from E75 ? GM-CSF-vaccinated HLA-A2? patients. 23, 24 Crystallographic analysis of the GP2 structure shows that the peptide center does not make stabilizing contacts with the binding cleft of the major histocompatibility complex (MHC) class I molecule. 25 It is therefore possible that the peptide assumes multiple conformations that can generate additional molecular surfaces recognized by various T-cell receptors. 24 Decreased affinity may lead to less immunologic tolerance. In this study, the data suggest that, for HLA-A3? patients, the binding of GP2 may not be sufficient to generate an effective immune response.
We observed an increased immunologic response to AE36, an immunogenic epitope from the HER2 intracellular domain, indicating epitope spreading, a broader immunologic response from proteolysis, and presentation of additional HER2 epitopes for recognition by the immune system. We have previously reported that vaccination with the E75 ? GM-CSF vaccine induces intra-and inter-antigenic epitope spreading, and have hypothesized that, for peptide vaccines to elicit a strong anti-tumor immune response, epitope spreading is likely essential. 23 
CONCLUSIONS
The data from this study support further evaluation of combination strategies employing a CD8 ? T-cell-eliciting vaccine with trastuzumab. We are currently conducting two such trials. One evaluates the E75 ? GM-CSF vaccine in combination with trastuzumab in patients with high-risk, HER2-positive breast cancer (NCT02297698). 26 High-risk patients have residual disease following neoadjuvant systemic therapy that includes anti-HER2-targeted therapy with trastuzumab (with or without pertuzumab), or, for those undergoing surgery as an initial intervention, significant nodal disease defined as any positive nodes in patients with hormone receptor-negative, HER2-positive tumors, or four or more positive nodes in patients with hormone receptor-positive, HER2-positive tumors. After completing surgical therapy, patients are randomized to receive either trastuzumab alone to complete 1 year (standard practice) or to receive trastuzumab, with the vaccine administered concurrently for six inoculations administered every 3 weeks 9 6. Booster inoculations are administered every 6 months out through 3 years to address waning immunity, which could contribute to late recurrences. The second trial assesses the same combination in patients with HER2 low-expressing tumors, i.e. IHC 1? or 2? (NCT01570036). 27 Patients are eligible if they are node positive, regardless of hormone receptor status, or if they are node negative and hormone receptor negative. While trastuzumab is clearly active in patients with HER2-positive breast cancer, 28 it is not currently approved for use in patients with HER2 low-expressing tumors. We noted in our previous phase I/II trials evaluating HER2-derived, CD8 T-cell-eliciting vaccines (enrolled patients who had tumors with any degree of HER2 expression) that vaccination resulted in stronger immunologic responses in patients with HER2 1? or 2? tumors. 19 This correlated with a decreased disease recurrence rate. We hypothesize that lower HER2 expression levels may lead to less immunologic tolerance. However, it is possible that low and intermediate HER2-expressing tumors could have insufficient antigen presentation, causing decreased recognition by peptide-stimulated cytotoxic T lymphocytes. The concurrent use of trastuzumab may create a synergistic effect via ADCC, promoting cross-presentation 5, 6 by promoting HER2 receptor internalization, with a subsequent increase in antigen processing and presentation, 29 leading to enhanced epitope spreading, and by stimulating an anti-HER2 CD4? helper T-cell response. 8 disclosures to declare. The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army Medical Center, the US Army Medical Department, the US Army Office of the Surgeon General, the Department of the Army, Department of Defense or the US Government.
